Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overexpression of miR-181a in ABC-like DLBCL cell lines (OCI-LY10 and U2932) resulted in G0/G1 cell cycle arrest, increased apoptosis, and decreased invasiveness. miRNA target prediction programs (miRanda, TargetScan, and miRDB) identified caspase recruitment domain-containing protein 11 (<i>CARD11</i>) as a putative miR-181a target.
|
31662757 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The mutation profile of CARD11 and CD79B were evaluated in 70 patients [DLBCL (N=30), non-DLBCL lymphomas (N=30), and reactive lymphadenopathy (N=10).
|
29734251 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aggressive activated B-cell like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) exploits a multi-protein complex of CARMA1, BCL10, and MALT1 (CBM complex), which normally conveys NF-κB signaling upon antigen receptors engagement.
|
30474008 |
2018 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations in the adapter protein CARD11 associated with diffuse large B cell lymphomas (DLBCLs) are predicted to arise during germinal center (GC) responses, leading to inappropriate activation of NF-κB signaling.
|
30127060 |
2018 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MYD88, CD79B, CD79A, and caspase recruitment domain family member 11 (CARD11) mutations were examined in samples from 40 patients with CD5<sup>+</sup> DLBCL.
|
27915469 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To this end, we expressed oncogenic CARMA1 in the NF-κB negative DLBCL lymphoma cell line BJAB.
|
26776161 |
2016 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Oncogenic CARD11 mutations associated with the activated B cell-like subtype of diffuse large B cell lymphoma somehow perturb ID-mediated autoinhibition to confer CARD11 with the dysregulated spontaneous signaling to NF-κB that is required for the proliferation and survival of the lymphoma.
|
26884334 |
2016 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Chronic active B cell receptor (BCR) signaling, a hallmark of the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), engages the CARD11-MALT1-BCL10 (CBM) adapter complex to activate IκB kinase (IKK) and the classical NF-κB pathway.
|
27070702 |
2016 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This autoinhibitory strategy makes CARD11 highly susceptible to gain-of-function mutations that are frequently observed in diffuse large B cell lymphoma (DLBCL) and that disrupt ID-mediated autoinhibition, leading to constitutive NF-κB activity, which can promote lymphoma proliferation.
|
26884335 |
2016 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Genomic landscape of cutaneous T cell lymphoma.
|
26192916 |
2015 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To investigate the consequences of dysregulated CARD11 signaling in vivo, we generated mice that conditionally express the human DLBCL-derived CARD11(L225LI) mutant.
|
26668357 |
2015 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Activating mutations of genes involved in the BCR and NF-κB pathways (CD79A, CD79B, MYD88, and CARD11) or in epigenetic regulation (EZH2) have been recently reported, preferentially in one of the two DLBCL subtypes.
|
24327543 |
2014 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
|
25049379 |
2014 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In a number of B-cell malignancies, activating mutations in signal transduction components of the BCR pathway have been identified; prominent examples are activated B-cell-like (ABC) diffuse large B-cell lymphomas (DLBCL) that carry mutations in CD79B and CARD11 and display chronic active BCR signaling resulting in constitutive activation of the NF-κB pathway.
|
24060900 |
2013 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma.
|
23632891 |
2013 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our study reports the incidence of TNFAIP3 and CARD11 alterations in Saudi DLBCL, a potentially unique ethnic group, and highlights for the first time the role of CARD11 gene amplification as a novel mechanism for NF-κB activation in Middle Eastern DLBCL.
|
22397314 |
2012 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recently, NF-κB canonical pathway genes including CARD11, CD79B and MYD88 were shown to be frequently mutated in diffuse large B-cell lymphomas.
|
22808296 |
2012 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The ABC subtype of DLBCL is associated with constitutive activation of the NF-κB pathway, and oncogenic lesions have been identified in its regulators, including CARD11/CARMA1 (caspase recruitment domain-containing protein 11), A20/TNFAIP3, and CD79A/B.
|
21324920 |
2011 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Expression of a DLBCL-derived mutant of the adaptor CARD11 (a constitutive activator of NF-κB) in the GCB-like human BJAB cell line or v-Rel in the chicken DT40 B-lymphoma cell line causes reduced expression of PU.1.
|
20947507 |
2011 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We investigated the genetic abnormalities of CARD11, A20, and ABIN-1/2/3 (the A20 binding inhibitor of NF-κB) and their clinicopathologic correlation in gastrointestinal DLBCL.
|
21266526 |
2011 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We conclude that mutations of the oncogene CARD11 may contribute to NF-kappaB activation and thereby play a role in the pathogenesis of PCNSL, while, in contrast to systemic DLBCL, inactivation of TNFAIP3 either by mutation or methylation seems to be of minor significance.
|
20544211 |
2010 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Several oncogenic CARD11 mutations have been identified in DLBCL that enhance activity and that are mostly found in the coiled-coil domain.
|
20799731 |
2010 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that CARD11 is a bona fide oncogenein DLBCL, providing a genetic rationale for the development of pharmacological inhibitors of the CARD11 pathway for DLBCL therapy.
|
18323416 |
2008 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This screen uncovered CARD11 as a key upstream signalling component responsible for the constitutive IkappaB kinase activity in activated B-cell-like DLBCL.
|
16572121 |
2006 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
CARMA1 and chromosomal translocations in extranodal marginal zone B-cell lymphomas of MALT type or diffuse large B-cell lymphomas.
|
17043017 |
2006 |